 Thrombolytic pharmacokinetic properties chimeric tissue-type urokinase-type plasminogen activators BACKGROUND Chimeric A-chain tissue-type plasminogen activator t-PA catalytic domain urokinase-type plasminogen activator u-PA intact enzymatic characteristics u-PA partial fibrin-binding properties t-PA thrombolytic properties animal models comparable superior single-chain u-PA scu-PA Deletion finger growth factor domains t-PA-delta FE/scu-PA-e chimeras reduces affinity fibrin METHODS RESULTS detailed investigation thrombolytic potency pharmacokinetics t-PA u-PA chimeras quantitative animal models thrombolysis hamsters pulmonary embolism rabbits jugular vein thrombosis baboons femoral vein thrombosis thrombolytic potency percent lysis milligram compound kilogram body weight t-PA-delta FE/scu-PA-e recombinant scu-PA rscu-PA Saruplase maximal rate versus lysis milligram compound kilogram body weight mean SEM hamsters versus lysis milligram compound kilogram body weight mean SEM rabbits versus lysis milligram compound kilogram body weight baboons specific thrombolytic activity percent lysis milliliter steady-state plasma level t-PA-delta FE/scu-PA-e different rscu-PA hamsters versus lysis milliliter antigen level rscu-PA rabbits versus lysis milliliter antigen level dogs combined femoral vein blood clot platelet-rich femoral arterial eversion graft thrombosis mg/kg body wt bolus injections t-PA-delta FE/scu-PA-e venous clot lysis mg/kg rscu-PA arterial side frequent dogs dogs persistent dogs none dogs recanalization bolus injection hamsters rabbits baboons t-PA-delta FE/scu-PA-e fourfold initial half-life rscu-PA plasma clearance sixfold hamsters rabbits baboons CONCLUSIONS results t-PA-delta FE/scu-PA-e thrombolytic potency venous arterial thrombi vivo clearance specific thrombolytic activity properties chimera useful thrombolytic therapy bolus administration patients thromboembolic disease